Literature DB >> 2221866

SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.

T J Walsh1, J W Lee, J Lecciones, P Kelly, J Peter, V Thomas, J Bacher, P A Pizzo.   

Abstract

To investigate the potential use of SCH-39304 for the prevention and treatment of disseminated candidiasis in granulocytopenic patients, we studied its in vivo antifungal activity as preventive, early, and late treatments in three models (acute, subacute, and chronic) of disseminated candidiasis in persistently granulocytopenic rabbits. SCH-39304 was an effective as amphotericin B alone and fluconazole alone for the prevention of disseminated candidiasis. SCH-39304 alone and fluconazole alone were as effective as amphotericin B plus flucytosine for early treatment of subacute disseminated candidiasis. When treatment was delayed for 5 days to establish chronic disseminated candidiasis, SCH-39304 was less effective than amphotericin B plus flucytosine. In comparison with different treatment regimens, SCH-39304 was more effective in early and preventive treatment. Thus, SCH-39304 was comparable to treatment control regimens in prevention and early treatment of subacute disseminated candidiasis. SCH-39304 also was most effective in granulocytopenic rabbits with disseminated candidiasis when used for prevention or early treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2221866      PMCID: PMC171873          DOI: 10.1128/AAC.34.8.1560

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits.

Authors:  J W Lee; C Lin; D Loebenberg; M Rubin; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

2.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 3.  Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents.

Authors:  J R Graybill
Journal:  Infect Dis Clin North Am       Date:  1988-12       Impact factor: 5.982

4.  Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans.

Authors:  T J Walsh; C McEntee; D M Dixon
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

5.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.

Authors:  D V Savani; J R Perfect; L M Cobo; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

Review 6.  Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts.

Authors:  T J Walsh; J Lee; S Aoki; F Mechinaud; J Bacher; J Lecciones; V Thomas; M Rubin; P A Pizzo
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 8.  Hepatic candidiasis in cancer patients: the evolving picture of the syndrome.

Authors:  M Thaler; B Pastakia; T H Shawker; T O'Leary; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.

Authors:  M Thaler; J Bacher; T O'Leary; P A Pizzo
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

View more
  6 in total

1.  Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Authors:  A Cacciapuoti; D Loebenberg; R Parmegiani; B Antonacci; C Norris; E L Moss; F Menzel; T Yarosh-Tomaine; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.

Authors:  P Mojaverian; E Radwanski; M B Affrime; M N Cayen; C C Lin
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

Authors:  D Loebenberg; A Cacciapuoti; R Parmegiani; E L Moss; F Menzel; B Antonacci; C Norris; T Yarosh-Tomaine; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Hydroxysulfonylation of alkenes: an update.

Authors:  Zinatossadat Hossaini; Evan Abdulkareem Mahmood; Mohammad Reza Poor Heravi; Abdol Ghaffar Ebadi; Esmail Vessally
Journal:  RSC Adv       Date:  2021-06-18       Impact factor: 4.036

Review 5.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

6.  Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.

Authors:  H S Jafari; X Sáez-Llorens; C Severien; F Parras; I Friedland; S Rinderknecht; S Ehrett; K D Olsen; C Abramowsky; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.